Subunit Vaccination Using Atomic Layering Thermostable Antigen and Adjuvant (ALTA(R)) Platform Elicits Enhanced Humoral and Cellular Immune Responses
Daria L. Ivanova, Matthew LewisiD, Annie B Caplan, Isabella R. WaltersiD, Emma M. Snyder, Keith A. StrandiD, Lorena R. AntúneziD, Sineenart SengyeeiD, Sarah B Weiby, Federico Urbano-Muñoz, Mary N. BurtnickiD, Paul J. BrettiD, Sky W. BrubakeriD
Abstract
AbstractCreating effective and thermostable vaccines is of significant relevance for public health. The Atomic Layering Thermostable Antigen and Adjuvant (ALTA(R)) platform combines spray drying to stabilize antigens in a sugar matrix followed by coating with atomic layer deposition (ALD) for temporal control over in vivo release. While these technologies have shown preliminary promise for different vaccine antigens, further characterizations of the immune response to ALTA(R) formulated antigens are still needed. Here, the immune response to ALTA(R) formulated antigens is described and compared to a set of adjuvanted liquid vaccine formulations that included Alhydrogel(R), AddaVax, and Alhydrogel(R)+CpG. The humoral and cell-mediated responses were measured by ELISA and flow cytometry. Increased and lasting antigen-specific antibody titers following administration of ALTA(R) containing ovalbumin (OVA) demonstrated robust and durable humoral response. Furthermore, ALTA(R) injected mice produced both IgG2c and IgG1 indicating a balanced Th1/Th2 response. Importantly, ALTA(R) OVA elicited robust humoral response at lower doses of aluminum than Alhydrogel(R). The most striking difference between ALTA(R) and the liquid vaccine formulations tested was a greater OVA-specific CD8+ T cell response observed at all antigen doses tested. Mechanistically, antigen encapsulation within ALTA(R) particles was critical for antibody production and CD8+ T cell responses as well as antigen capture by antigen-presenting cells (APCs) at the site of injection and draining lymph nodes. To test these concepts in a more physiological application, protein and polysaccharide vaccine antigens derived from a facultative intracellular bacterium Burkholderia pseudomallei, the causative agent of melioidosis, were formulated using the ALTA(R) platform. Compared to liquid vaccine formulations, ALTA(R) immunized mice showed enhanced antigen-specific antibody production and IFN-{gamma} secreting T cell responses using lower adjuvant doses of aluminum and CpG. Overall, ALTA(R) formulated protein and polysaccharide antigens elicited strong humoral and cell-mediated immunity suggesting potential broad applicability of the platform to vaccines against various diseases, including against cancer and infections from intracellular pathogens.
02 /Specification & Classification
Click any tag to browse matching papers- Citations
- 2
- FWCI
- 5.28
- Field percentile
- top 5%
- Organism
- Assay
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Atomic Layering Thermostable Antigen and Adjuvant (ALTA(R)) platform provides unique antigen delivery system through controlled release to improve immune response to vaccination
Keith A. Strand, Heather D’Angelo, … Sky W. Brubaker·bioRxiv·Jan 5, 2026
- Atomic layer deposition for core-shell microparticle vaccines enabling programmable antigen delivery and enhanced humoral immune responses
Namit Chaudhary, Holly Coleman, … Darrell J. Irvine·bioRxiv·Sep 2, 2026
- Improved humoral immunity and protection against influenza virus infection with a 3D porous biomaterial vaccine
H. Miwa, O. Q. Antao, … D. Di Carlo·bioRxiv·Dec 16, 2022
- A TLR7 Agonist Conjugated to a Nanofibrous Peptide Hydrogel as a Potent Vaccine Adjuvant
Erin M. Euliano, Brett H. Pogostin, … Kevin J. McHugh·Advanced Healthcare MaterialsPeer-reviewed·Oct 25, 2024
- Broad heterologous protection against Influenza A viruses by an adjuvant-free modular mucosal T-cell vaccine platform.
Rajesh Thangavel Yadav, Mansi Sharma, … S.K. Tripathi·bioRxiv·Jun 5, 2026
- Effects of aluminum-salt, CpG and emulsion adjuvants on the stability and immunogenicity of a virus-like particle displaying the SARS-CoV-2 receptor binding domain (RBD)
O. S. Kumru, S. Bajoria, … D. B. Volkin·bioRxiv·Jul 10, 2023